This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
The original data of this study can be obtained via e-mail to Prof. I. Kotsianidis (email@example.com).
Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383:2239–52.
Najean Y, Lecompte T. Chronic pure thrombocytopenia in elderly patients. An aspect of the myelodysplastic syndrome. Cancer. 1989;64:2506–10.
Qian J, Xue Y, Pan J, Cen J, Wang W, Chen Z. Refractory thrombocytopenia, an unusual myelodysplastic syndrome with an initial presentation mimicking idiopathic thrombocytopenic purpura. Int J Hematol. 2005;81:142–7.
Kuroda J, Kimura S, Kobayashi Y, Wada K, Uoshima N, Yoshikawa T. Unusual myelodysplastic syndrome with the initial presentation mimicking idiopathic thrombocytopenic purpura. Acta Haematol. 2002;108:139–43.
Menke DM, Colon-Otero G, Cockerill KJ, Jenkins RB, Noel P, Pierre RV. Refractory thrombocytopenia. A myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. Am J Clin Pathol. 1992;98:502–10.
Sashida G, Takaku TI, Shoji N, Nishimaki J, Ito Y, Miyazawa K, et al. Clinico-hematologic features of myelodysplastic syndrome presenting as isolated thrombocytopenia: an entity with a relatively favorable prognosis. Leuk Lymphoma. 2003;44:653–8.
Breccia M, Latagliata R, Cannella L, Carmosino I, Santopietro M, Loglisci G, et al. Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients. Leuk Lymphoma. 2010;51:783–8.
Waisbren J, Dinner S, Altman J, Frankfurt O, Helenowski I, Gao J, et al. Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia. Int J Hematol. 2017;105:44–51.
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19.
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood. 2022;140:1200–28.
Arnold DM. Bleeding complications in immune thrombocytopenia. Hematol Am Soc Hematol Educ Program. 2015;2015:237–42.
Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, et al. Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis. Br J Haematol. 2016;175:975–9.
Gupta R, Soupir CP, Johari V, Hasserjian RP. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol. 2007;139:265–8.
Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829–66.
Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3:3780–817.
We would like to thank all local investigators for their contribution to data acquisition for the Hellenic National Registry of Myelodysplastic and Hypoplastic Syndromes and the ITP Registry of the Hellenic Society of Hematology. We declare no funding for this research from any funding agency in the public, commercial, or not-for-profit sectors. There was no external funding for this research from any funding agency in the public, commercial or not-for-profit sectors.
IK, NAV, AS, and V. Pappa have received research funding from Celgene Corporation for work outside this study. IK, SGP, TPV, AGG, EH, PP, AK, AS, V. Pappa and NAV have received honoraria from Genesis Pharma Hellas S.A. for work outside this study. All other authors: no conflicts of interest.
This study was approved by the Ethics Committee of the Hellenic Society of Hematology (Protocol: No.8/26-3-2008). This study was done in accordance with the ethical standards of the Institutional Research Committees of the participating centers, and in compliance with the ethical principles of the Declaration of Helsinki.
The basis for this study formed the database of the Hellenic National Registry of Myelodysplastic and Hypoplastic Syndromes (N = 2972 patients) and the database of the ITP Registry of the Hellenic Society of Hematology (N = 1317 patients). All data were collected during routine patient care. This study was approved by the Ethics Committee of the Hellenic Society of Hematology (Protocol: No.8/26-3-2008).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Liapis, K., Papadopoulos, V., Pontikoglou, C. et al. Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries. Leukemia 37, 708–711 (2023). https://doi.org/10.1038/s41375-023-01819-x